Plain-English translation of NCT06766305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new immunotherapy drug called QL1706 combined with chemotherapy (SOX) for people with advanced stomach or gastroesophageal junction cancer that can be surgically removed. The trial will give you the medication before surgery to try to shrink the tumor, then you'll have surgery, and then continue the medication afterward to help prevent the cancer from returning.
Current treatments for advanced stomach cancer have limited success rates. This medication is designed to work with the immune system in a new way, and researchers hope that combining it with chemotherapy before and after surgery will improve survival and cure rates for patients with this aggressive cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication by intravenous infusion combined with chemotherapy pills for 3 cycles before surgery (approximately 9 weeks). Then you would have surgery to remove the tumor. After surgery, you would receive the medication combined with chemotherapy for 5 more cycles, followed by the medication alone as maintenance therapy for up to one year. You would have regular clinic visits, blood tests, and scans to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China